Algorithms, artificial intelligence, machine learning and other technologies are transforming the way physicians identify, treat and manage diseases. Here’s how Johnson & Johnson is putting the latest tools to work.
That's exactly what researchers at Johnson & Johnson are trying to find out. By partnering on a new study that's looking at the role gut microbes may play in the disease—and focusing on the underrepresented groups most affected—they hope to advance early-detection strategies and potential treatments.
Hidden in large amounts of digital information—such as anonymized medical records—may be the keys to transforming the future of healthcare. Troy C. Sarich, Ph.D., Johnson & Johnson's Chief Commercial Data Science Officer, shares how the company is carefully collecting, analyzing and harnessing this information to improve the health of people everywhere.
Artificial intelligence-enabled mobile screening units. Nasal swab genomic tests. Diagnostics that pair the right treatment with the right patient. For Lung Cancer Awareness Month, Johnson & Johnson researchers share the progress that's being made to thwart the #1 cancer killer.
Certain gene mutations can dramatically increase the risk of developing aggressive prostate cancer. That's why Johnson & Johnson is researching a new way to fight the disease—one that involves blocking cancer cells from repairing their own damaged DNA.
Most people know about side effects, like hair loss, that can accompany cancer treatment. But chemotherapy can also impact your skin. Oncodermatologists and Johnson & Johnson scientists looked into how to care for such skin—leading to a new science-backed line of cleansers, moisturizers and balms designed with cancer patients in mind.
In addition to its own cadre of scientists hard at work fighting the pandemic, Johnson & Johnson also supports external researchers and entrepreneurs equally dedicated to finding solutions for the current health crisis. We take a look at some of this groundbreaking work happening across the globe—from San Francisco to Seoul.
When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.
Siddhartha Mukherjee, M.D., made his name as an oncologist, researcher and Pulitzer Prize-winning writer. Now he's the scientific adviser of an immuno-oncology start-up that's tackling a rare form of leukemia. In an exclusive interview, he reveals his vision for the future of cancer treatments.
Some 20% of people diagnosed with the disease haven't touched a cigarette. For Healthy Lung Month, scientists who've dedicated their research to defeating lung cancer discuss why early detection is so key—and what you can do to protect yourself.
Johnson & Johnson aspires to change the trajectory of health for humanity. And Tom Heyman helps make that lofty goal a reality through his work as the head of Johnson & Johnson's venture capital division, which invests in dozens of companies each year. He shares what's on his radar for 2019.